Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 211 to 220 of 1090 total matches.
Rivaroxaban (Xarelto) plus Aspirin for Secondary Prevention of Cardiovascular Events
The Medical Letter on Drugs and Therapeutics • Dec 03, 2018 (Issue 1561)
. Lancet
2018; 391:219.
7. Drug Interactions from The Medical Letter. Available at: https ...
The FDA has approved a new 2.5-mg formulation of
the direct factor Xa inhibitor rivaroxaban (Xarelto –
Janssen) for use in combination with low-dose aspirin
to reduce the risk of major cardiovascular events in
patients with chronic coronary artery disease (CAD)
or peripheral artery disease (PAD). Rivaroxaban is
the first direct oral anticoagulant to be approved for
this indication. It was approved earlier for prevention
and treatment of deep vein thrombosis (DVT) or
pulmonary embolism (PE) and for prevention of stroke
and systemic embolism in patients with nonvalvular
atrial...
Sirolimus (Rapamune) for Transplant Rejection
The Medical Letter on Drugs and Therapeutics • Feb 07, 2000 (Issue 1071)
INTERACTIONS — Sirolimus, like tacrolimus and cyclosporine, theoretically could
interact with any drug ...
Sirolimus, whlch is structurally related to tacrolimus, has been approved by the FDA for prevention of acute renal transplant rejection. The manufacturer recommends that sirolimus be taken with cyclosporine and corticosteroids.
In Brief: Tegaserod (Zelnorm) Withdrawn
The Medical Letter on Drugs and Therapeutics • May 07, 2007 (Issue 1260)
: Jean-Marie Pflomm, Pharm.D.
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten,
Pharm.D ...
Tegaserod maleate (Zelnorm – Novartis), a partial serotonin 5-HT4 receptor agonist that increases gastrointestinal motility, was approved by the FDA in 2002 for short-term treatment of constipation-predominant irritable bowel syndrome in women,1 and in 2004 for treatment of chronic constipation in adults ≤65 years old. Its efficacy has not been impressive statistically, but according to Medical Letter consultants some patients with slow-transit constipation have benefited from taking the drug. Diarrhea has been its main adverse effect.2The FDA now has requested that the manufacturer stop...
Radium-223 (Xofigo) for Prostate Cancer
The Medical Letter on Drugs and Therapeutics • Sep 30, 2013 (Issue 1426)
was similar in both groups.
DRUG INTERACTIONS — No drug interaction studies
have been conducted with radium ...
Radium Ra 223 dichloride (Xofigo – Bayer), a radiotherapeutic
drug, has been approved by the FDA for
intravenous treatment of castration-resistant prostate
cancer with symptomatic bone metastases and no
known visceral metastatic disease.
Lurasidone (Latuda) for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Feb 21, 2011 (Issue 1358)
) according to the manufacturer.
DRUG INTERACTIONS — Concurrent use of strong
CYP3A4 inhibitors may increase ...
The FDA has approved lurasidone (Latuda - Sunovion), a new second-generation antipsychotic,
for oral treatment of schizophrenia in adults.
Opill — An OTC Oral Contraceptive
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023 (Issue 1685)
in the risk of
breast cancer.8,9
DRUG INTERACTIONS — Drugs that induce hepatic
enzyme activity ...
The FDA has approved Opill (Perrigo), a progestin-only
oral contraceptive that contains norgestrel, for
sale over the counter (OTC). Opill is the first oral
contraceptive to be approved in the US for sale without
a prescription. Approval of OTC Opill is intended
to increase access to effective contraception and
reduce the rate of unintended pregnancies.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):151-2 doi:10.58347/tml.2023.1685c | Show Introduction Hide Introduction
In Brief: Sevelamer-Based Phosphate Binders
The Medical Letter on Drugs and Therapeutics • Feb 25, 2008 (Issue 1280)
of Michigan Medical School
Lauren K. Schwartz, M.D., Mount Sinai School of Medicine
DRUG INTERACTIONS FELLOW ...
Sevelamer carbonate (Renvela – Genzyme), a buffered form of the anion-exchange resin sevelamer hydrochloride (Renagel – Genzyme),1 has been approved by the FDA for use in patients with chronic kidney disease on dialysis. According to the manufacturer, Renvela will replace Renagel, which has been shown to induce or exacerbate metabolic acidosis in patients on dialysis. Two randomized, crossover studies found the two sevelamer salts equivalent in their ability to lower serum phosphate.2,3 Patients taking the carbonate had higher serum bicarbonate concentrations and fewer gastrointestinal...
Tobramycin Inhalation Powder (Tobi Podhaler) for Cystic Fibrosis
The Medical Letter on Drugs and Therapeutics • Jun 24, 2013 (Issue 1419)
concentrations associated with inhalation
are harmful to the fetus is unknown.
DRUG INTERACTIONS — In clinical ...
Inhaled antibiotics, which can achieve high concentrations
in the lung with minimal systemic side effects, are
probably the most effective therapy available for chronic
Pseudomonas aeruginosa infection in patients with
cystic fibrosis. An orally inhaled dry powder formulation
of the aminoglycoside antibiotic tobramycin (Tobi
Podhaler – Novartis) has been approved by the FDA for
management of P. aeruginosa pulmonary infection in
cystic fibrosis patients ≥6 years old. The new formulation
is administered via a hand-held pocket-sized inhaler.
Tobramycin is also available as an...
Elagolix (Orilissa) - An Oral GnRH Antagonist for Endometriosis Pain
The Medical Letter on Drugs and Therapeutics • Sep 24, 2018 (Issue 1556)
.
DRUG INTERACTIONS — Elagolix is a weak to
moderate inducer, as well as a substrate, of CYP3A ...
The FDA has approved elagolix (Orilissa – AbbVie),
an oral gonadotropin-releasing hormone (GnRH)
antagonist, for management of moderate to severe
pain associated with endometriosis.
Angeliq for Treatment of Menopausal Symptoms
The Medical Letter on Drugs and Therapeutics • Feb 12, 2007 (Issue 1254)
significant changes in potassium levels.
DRUG INTERACTIONS — Estrogens are partly
metabolized by CYP3A4 ...
A combination tablet containing estradiol and drospirenone (Angeliq - Berlex) recently became available for treatment of moderate to severe menopausal symptoms in women with an intact uterus. Since the last Medical Letter issue reviewing such devices,1 more continuous glucose monitoring (CGM) systems have become available. Five devices available now, and two expected to be marketed soon, are listed in the table on page 14. The FDA has approved continuous glucose devices only for the observation of glucose trends.